Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Ocean Biomedical, Inc.
Ocean Biomedical, Inc. News
Jan 29, 2025 - globenewswire.com
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
Nov 22, 2024 - globenewswire.com
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Oct 22, 2024 - globenewswire.com
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
Oct 15, 2024 - globenewswire.com
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
Ocean Biomedical, Inc. Quantitative Score
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Ocean Biomedical, Inc. Earnings & Revenue
Ocean Biomedical, Inc. Financials
Table Compare
Compare OCEA metrics with: | |||
|---|---|---|---|
Earnings & Growth | OCEA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OCEA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OCEA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OCEA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Ocean Biomedical, Inc. Income
Ocean Biomedical, Inc. Balance Sheet
Ocean Biomedical, Inc. Cash Flow
Ocean Biomedical, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Ocean Biomedical, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Ocean Biomedical, Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert John Sweeney | Chief Accounting Officer & Assistant Secretary |
| Dr. Jonathan Kurtis M.D., Ph.D. | Founder, Chairman of Scientific Advisory Board & Director |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder & Executive Chairman of the Board |
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert John Sweeney | Chief Accounting Officer & Assistant Secretary | Male | 1965 | -- |
| Dr. Jonathan Kurtis M.D., Ph.D. | Founder, Chairman of Scientific Advisory Board & Director | 1968 | -- | |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer | 1967 | -- | |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder & Executive Chairman of the Board | 1965 | -- | |
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer | Female | 1965 | -- |
Ocean Biomedical, Inc. Insider Trades
| Date | 14 Feb |
| Name | Poseidon Bio, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 14 Feb |
| Name | Poseidon Bio, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 18582930 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Feb | Poseidon Bio, LLC | 10 percent owner | Disposed | 0 | |
| 14 Feb | Poseidon Bio, LLC | 10 percent owner | Disposed | 18582930 |